Papovaviruses are DNA viruses with very small genomes;yet they are both transforming and tumorigenic. The human Papilloma viruses are well-established malignant tumor-generating agents in man. Polyoma virus is a murine carcinogen, and recent evidence suggests that an SV40-like agent triggers the development of an aggressive human skin cancer. These viruses each encode a very small number of proteins, of which only a fraction act to elicit a neoplastic phenotype and to sustain tumor development. Through their analysis, major insights into widely encountered molecular events that trigger and maintain a neoplastic state have emerged. In this Program renewal application, an interactive research plan aimed at gaining ever deeper mechanistic understanding of papovaviral transformation and tumorigenesis is proposed. Six projects will, collectively, investigate major mysteries in the field: how cells escape and how they reenter the cell cycle, both naturally and when stimulated by papovaviral T antigens;why and how two related papovaviral small T antigens can act as an oncogene and as a potential tumor suppressor, respectively;how papovaviral small T perturbation of the protein phosphatase, PP2A, triggers powerful transforming signals through corruption of specific cellular signal transduction events;why and how SV40 large T antigen engages a mitotic checkpoint kinase as a key event in its transforming action;and how a papilloma virus regulatory protein (E2) operates as a tumor suppressing element. The goal of this Program is to continue to shed new light on cellular transformation events that also underpin human cancer development and generate insights that lead to new cancer therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA050661-24
Application #
8265331
Study Section
Special Emphasis Panel (ZCA1-GRB-S (J1))
Program Officer
Read-Connole, Elizabeth Lee
Project Start
1997-04-10
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
24
Fiscal Year
2012
Total Cost
$2,776,746
Indirect Cost
$850,841
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Pores Fernando, A T; Andrabi, S; Cizmecioglu, O et al. (2015) Polyoma small T antigen triggers cell death via mitotic catastrophe. Oncogene 34:2483-92
Luo, Leo Y; Kim, Eejung; Cheung, Hiu Wing et al. (2015) The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Mol Cancer Res 13:502-9
Smith, Jennifer A; Haberstroh, Friederike S; White, Elizabeth A et al. (2014) SMCX and components of the TIP60 complex contribute to E2 regulation of the HPV E6/E7 promoter. Virology 468-470:311-21
Shao, Diane D; Xue, Wen; Krall, Elsa B et al. (2014) KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158:171-84
White, Elizabeth A; Walther, Johanna; Javanbakht, Hassan et al. (2014) Genus beta human papillomavirus E6 proteins vary in their effects on the transactivation of p53 target genes. J Virol 88:8201-12
Utermark, Tamara; Schmit, Fabienne; Lee, Sang Hyun et al. (2014) The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type. J Virol 88:10673-9
DeCaprio, J A (2014) Human papillomavirus type 16 E7 perturbs DREAM to promote cellular proliferation and mitotic gene expression. Oncogene 33:4036-8
Schmit, Fabienne; Utermark, Tamara; Zhang, Sen et al. (2014) PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 111:6395-400
DeCaprio, James A; Duensing, Anette (2014) The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors. Curr Opin Oncol 26:415-21
Naetar, Nana; Soundarapandian, Velmurugan; Litovchick, Larisa et al. (2014) PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length. Mol Cell 54:932-45

Showing the most recent 10 out of 124 publications